Autologous TIL therapy is an immunotherapeutic approach that leverages the patient’s own immune system to combat malignant cells. TILs are lymphocytes naturally present within a tumor, harboring the innate capability to recognize cancer-specific antigens. The therapeutic process involves surgically extracting these lymphocytes from tumor biopsies, expanding them ex vivo to quantities often reaching into the hundreds of millions, and infusing them back into the patient. This infusion aims to augment the immune response by saturating the body with highly active, tumor-specific lymphocytes capable of targeting and dismantling cancer cells more effectively than the patient’s unassisted immune system.

The impetus for this trial stems from earlier observational studies indicating that higher levels of TILs within tumors correlate with improved disease-free survival rates among HNSCC patients. This established an immunological rationale for enhancing TIL presence therapeutically, particularly within the context of recurrent or metastatic disease where conventional therapies—such as chemotherapy, radiation, and surgery—have often failed. The phase 2 trial enrolled 53 patients categorized into four distinct treatment arms, which allowed for a comparative assessment of various TIL formulations. These included non-cryopreserved TILs, cryopreserved lifileucel—an FDA-approved T-cell therapy previously validated in metastatic melanoma—non-cryopreserved lifileucel, and a cryopreserved TIL therapy enriched for PD-1 positive cells. PD-1 is an immune checkpoint receptor commonly expressed on T cells, acting as a marker for tumor-reactive lymphocytes.

Participants in the study predominantly consisted of males, with a median age of 57 years, suffering from late-stage metastatic HNSCC. The median duration of treatment exposure was approximately 17.9 months, and the median response to therapy lasted 7.6 months, though some patients experienced disease stabilization for nearly two years. Impressively, 64% of patients across the cohorts achieved stabilization of cancer progression—a benchmark that, until this study, had been elusive for this clinical population. The median overall survival was reported to be 9.5 months, a figure that notably surpasses existing outcomes for similar patient groups who have exhausted standard care options.

Side effect profiles were consistent with expectations for TIL-based therapies, which can prompt systemic inflammatory responses due to lymphocyte activation. The most prevalent non-hematologic adverse events included chills, experienced in 60% of patients, hypotension in 53%, and fever in 47%. Hematologic toxicities manifested as thrombocytopenia and anemia, with incidences of 74% and 53%, respectively. These side effects, while notable, were generally manageable with supportive care. The trial’s safety data reinforce the feasibility of administering TIL therapies to this fragile cohort without incurring unacceptable toxicity.

Robert L. Ferris, MD, PhD, who led the investigation while at UPMC Hillman Cancer Center and subsequently analyzed the findings as executive director at UNC Lineberger, underscored the significance of the outcomes. Ferris highlighted that these patients usually have limited life expectancy due to aggressive disease and prior treatment failures. The approximate nine-month extension in survival attributable to TIL therapy represents a meaningful clinical breakthrough, underscoring the importance of immunotherapeutic strategies in refractory solid tumors.

Despite these encouraging results, Ferris and colleagues acknowledged challenges inherent to the therapy’s broader applicability. The relatively small patient populations in each treatment arm limited the ability to perform direct statistical comparisons, emphasizing the necessity for larger, randomized controlled trials to comprehensively ascertain efficacy. Furthermore, questions remain regarding the optimization of TIL manufacturing—whether fresh or cryopreserved cells yield superior clinical outcomes—as well as the identification of synergistic combination regimens that could potentiate anti-tumor effects while mitigating immune evasion.

Of particular interest is the enrichment for PD-1 positive TILs, leveraging the understanding that these cells bear markers of prior tumor engagement and potential exhaustion. Modulating this population through adjunctive therapies, such as immune checkpoint inhibitors, might amplify the therapeutic durability of TIL infusions. Exploring these combinations could usher in a new paradigm in HNSCC treatment, providing not just disease stabilization but meaningful regression and long-term remission.

Head and neck squamous cell carcinoma remains a significant clinical challenge worldwide, accounting for approximately 3.6% of all new cancers in the United States, with nearly 60,000 diagnoses anticipated in 2025 alone. The notoriously aggressive nature of metastatic HNSCC, combined with frequent resistance to chemo- and radiotherapies, underscores the urgency of novel immunotherapies. The present study’s findings affirm the potential of individualized cell-based immunotherapies to fill this critical therapeutic void.

Underlying the trial’s success was a collaboration with Iovance Biotherapeutics, the manufacturer of lifileucel, ensuring access to cutting-edge cell manufacturing technologies. Lifileucel’s prior approval for metastatic melanoma provided a precedent for its adaptation in HNSCC, and the current findings could expand the therapeutic indications for this biologic agent. Moving forward, the results pave the way for subsequent large-scale studies designed to evaluate TIL therapy head-to-head against current standards of care, possibly reshaping treatment algorithms within oncology.

As the field of cancer immunotherapy evolves, the implications of TIL therapy extend beyond head and neck cancers. Enhancing the precision of adoptive T-cell therapies, optimizing cell culture conditions, and refining patient selection criteria hold promise for improving outcomes across various malignancies. This trial stands as a landmark step, illuminating the path toward harnessing the patient’s own immune system to tackle some of the most intractable cancers known to medicine.

In summary, the phase 2 clinical trial of autologous TIL therapy in recurrent and metastatic head and neck squamous cell carcinoma offers a compelling narrative of hope and scientific rigor. With the therapy demonstrating a tangible survival benefit and manageable safety profile, the findings invigorate the quest for personalized immunotherapies. Future research is expected to focus on combination modalities, refined manufacturing processes, and randomized trials that will ultimately define the clinical utility of TIL therapy in oncology practice.

Subject of Research: People

Article Title: Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

News Publication Date: 24-Aug-2025

Web References:
https://jitc.bmj.com/lookup/doi/10.1136/jitc-2025-011633

Image Credits: UNC Lineberger Comprehensive Cancer Center

Keywords: Cancer, Immunology, Cancer immunology, Immunotherapy, Head and neck cancer, Lymphocytes

This new study, led by Dr. Antonio Jimenez Jimenez of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, systematically explores the efficacy of using partially matched unrelated donors combined with novel GVHD prophylaxis regimens. By employing post-transplant cyclophosphamide—an immune-suppressing chemotherapy traditionally used in marrow transplants—to mitigate GVHD risk, researchers have expanded the feasible donor pool without compromising patient outcomes. Results from the phase 2, nonrandomized clinical trial reveal that one-year survival rates and rates of moderate to severe chronic GVHD in recipients of 6/8 or 7/8 matched donors parallel those in patients receiving fully matched grafts.

Hemopoietic cell transplantation remains a potentially curative therapy for various hematologic malignancies including leukemia, lymphoma, and myelodysplastic syndromes. Despite its curative potential, the procedure’s success has depended heavily on the presence of an HLA-matched donor, limiting treatment accessibility for many patients. Given that approximately 25% of patients with siblings may find a full match within their family, and considering the National Marrow Donor Program (NMDP) registry’s over 42 million donors worldwide, the barriers remain formidable, especially for racial and ethnic minorities. This new evidence fundamentally challenges pre-existing paradigms by suggesting that partial matches, under appropriate immune modulation, can suffice to yield favorable transplant outcomes.

Cyclophosphamide’s role in post-transplant care has evolved remarkably. Historically administered pre-transplant as a conditioning agent, its application several days post-transplant capitalizes on its selective ability to eliminate alloreactive T cells responsible for GVHD, while sparing regulatory and hematopoietic progenitor cells. This immunomodulatory property allows for greater tolerance of mismatched HLA antigens, effectively balancing graft-versus-leukemia effects with GVHD risk. The study harnessed this mechanism in combination with additional immune suppressants, employing either reduced-intensity conditioning (RIC), nonmyeloablative conditioning (NMA), or myeloablative conditioning (MAC) to optimize outcomes across patient populations of varying clinical fitness levels.

The trial enrolled 145 adult patients who lacked matched donors and underwent peripheral blood stem cell transplantation sourced through the NMDP. The shift from bone marrow to peripheral blood stem cells as a graft source has been increasingly prevalent, offering advantages such as more rapid engraftment and immune reconstitution. Strikingly, the majority of donors were HLA-matched at only 6/8 or 7/8 loci, yet patients experienced robust one-year survival rates, specifically 78.6% in the RIC/NMA subgroup and 83.8% in those conditioned with MAC. Concurrently, incidences of moderate-to-severe chronic GVHD were impressively low, underscoring the regimen’s high tolerability and safety.

An important aspect of the findings is that patients with lower HLA match levels did not experience inferior outcomes compared to those with higher match degrees. This parity in clinical endpoints not only supports implementation in clinical practice but also signals a paradigm shift—transplant physicians can now prioritize donor attributes beyond HLA compatibility, including donor availability, age, and cytomegalovirus serostatus. Expanding the donor pool through permissive mismatches where appropriate reduces wait times, allowing more patients timely access to potentially curative transplantation.

This trial, conducted through a highly collaborative network involving 21 centers under the sponsorship of the NMDP and the Center for International Blood and Marrow Transplant Research (CIBMTR), underscores the power of cooperative clinical research efforts. The NMDP’s extensive registry infrastructure facilitates rapid identification and procurement of grafts from international donors, bridging geographic and demographic gaps in donor candidacy. The study’s results echo smaller prior investigations and align with evidence demonstrating the efficacy of post-transplant cyclophosphamide in related donor settings, further reinforcing its broad applicability.

From a mechanistic standpoint, the study elucidates how cyclophosphamide’s timing and dose calibrate immune balance. Administered post-transplant, it targets rapidly proliferating alloreactive T cells responsible for acute and chronic GVHD without abolishing the beneficial graft-versus-leukemia effect crucial for eradicating malignant cells. Additionally, combining it with other immunosuppressive agents and varied conditioning intensities accommodates patient heterogeneity, especially important for older or more medically frail individuals who may not tolerate myeloablative regimens.

Looking beyond immediate transplantation outcomes, the research team continues to longitudinally evaluate longer-term survival, relapse rates, and late-onset complications among this patient cohort. Furthermore, ongoing trials are investigating lower cyclophosphamide dosing schedules aimed at reducing infection risks, a known complication of immunosuppression, and exploring alternative drug combinations to optimize GVHD prophylaxis further. Pediatric cohorts are also being assessed, promising to broaden applicability across the age spectrum.

This work also addresses a critical health equity concern. While patients from well-represented ethnic populations have approximately a 70% probability of finding a full donor match in registries, those from underrepresented minorities face markedly diminished chances. By expanding permissible mismatches with effective GVHD prevention, this protocol offers hope for reducing disparities in access to life-saving transplantation therapies, a historic challenge in hematologic oncology.

Dr. Jimenez Jimenez emphasizes the necessity of this innovation, calling the trial a response to an urgent clinical need. The study exemplifies translational research where scientific discovery directly informs patient care protocols, expanding not only the donor pool but also the therapeutic options for complex, high-risk patients. The global recognition garnered by Sylvester’s transplant program further highlights their leadership role in pioneering these advancements.

In summary, this pivotal study recalibrates the boundaries of donor compatibility in hematopoietic stem cell transplantation, demonstrating that partial HLA matches combined with the strategic use of post-transplant cyclophosphamide can achieve outcomes previously thought exclusive to fully matched grafts. For patients with blood cancers, this research translates to increased access to potentially curative transplants, reduced waiting times, and personalized donor selection strategies, marking a major milestone in the evolution of hematopoietic transplantation medicine.

Subject of Research: Hematopoietic stem cell transplantation using partially HLA-matched unrelated donors with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis.

Article Title: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

News Publication Date: June 26, 2025

Web References:

• https://ascopubs.org/doi/10.1200/JCO-25-00856
• https://clinicaltrials.gov/study/NCT04904588
• http://nmdp.org/
• https://umiamihealth.org/en/sylvester-comprehensive-cancer-center

References: Available within the Journal of Clinical Oncology article.

Image Credits: Photo by Sylvester Cancer Center

Keywords: Hematology, Transplantation, Blood diseases, Blood cancer, Tissue transplantation, Bone marrow transplantation

The study, known as ALEK-B, assessed this combination as a first-line treatment option, challenging current standards that typically rely upon monotherapy with targeted ALK inhibitors. For years, alectinib has been a front-runner among ALK inhibitors, exhibiting potent activity against ALK-rearranged NSCLC and yielding improved progression-free survival compared to earlier generations of targeted drugs. However, the emergence of resistance mechanisms and intratumoral heterogeneity have limited its long-term effectiveness. By synergizing with bevacizumab, which disrupts tumor vasculature and starves cancer cells of essential nutrients, the therapy aims to augment anti-tumor responses and delay resistance development.

The trial was designed as a single-arm, phase 2 study encompassing a cohort of patients diagnosed with ALK-positive NSCLC who had not received prior systemic therapy. This design allowed investigators to meticulously evaluate the safety profile, objective response rates, and durability of clinical responses directly attributable to the combination treatment, bypassing confounding variables present in randomized controlled trials. Researchers employed rigorous inclusion criteria, ensuring patient homogeneity based on molecular diagnostics confirming ALK rearrangements through fluorescence in situ hybridization and next-generation sequencing techniques.

From a mechanistic standpoint, alectinib inhibits the aberrant tyrosine kinase activity resulting from ALK fusion proteins, which drive proliferation and survival in affected cancer cells. Bevacizumab, conversely, targets vascular endothelial growth factor A (VEGF-A), a pivotal mediator of angiogenesis. By neutralizing VEGF-A, bevacizumab reduces neovascularization, consequently impairing tumor oxygenation and nutrient supply. The rationale for this dual approach rests on the hypothesis that suppressing both the molecular oncogenic driver and its supportive microenvironment will yield synergistic antitumor effects stronger than monotherapies alone.

Results from the ALEK-B trial demonstrated encouraging outcomes. Patients receiving the combination experienced significant tumor shrinkage, with objective response rates exceeding historical controls treated with alectinib alone. Furthermore, progression-free survival data suggested prolonged disease control, while preliminary overall survival metrics painted an optimistic picture of extending patient lifespan beyond what current therapies offer. Importantly, the safety profile reported in the trial indicated manageable adverse events consistent with known toxicities of the individual agents, reinforcing the feasibility of combining these two targeted therapies in clinical practice.

One of the notable breakthroughs of this regimen is its potential to circumvent or delay the emergence of resistance mutations on the ALK gene, a formidable challenge in targeted lung cancer therapies. Resistance to ALK inhibitors often emerges through secondary mutations or alternative signaling pathway activation. By concurrently impairing angiogenesis, bevacizumab introduces a novel therapeutic pressure that may reduce tumor adaptability, curtail clonal evolution, and foster more durable responses.

The implications of the ALEK-B trial extend beyond immediate clinical benefits. This work represents a paradigm shift emphasizing combination regimens that integrate targeted kinase inhibition with tumor microenvironment modulation, encouraging future exploration of similar strategies across diverse oncogenic drivers and solid tumors. Additionally, this trial underscores the significance of biomarker-driven enrollment, ensuring that patients most likely to benefit from such tailored interventions are identified and treated accordingly.

While the ALEK-B study provides compelling evidence for the clinical utility of alectinib plus bevacizumab, further randomized studies are warranted to firmly establish this regimen as a new standard of care. Ongoing trials with larger sample sizes and longer follow-ups will clarify the durability of responses, optimal dosing schedules, and potential synergistic toxicities. Equally important will be investigating resistance mechanisms that may arise during combined therapy, which could inform iterative improvements in treatment design.

On a molecular level, the study sparks intense curiosity about how angiogenesis inhibition influences the tumor microenvironment in ALK-rearranged NSCLC. Beyond just pruning blood vessels, VEGF blockade has been implicated in modulating immune cell infiltration, stromal interactions, and hypoxia-driven signaling cascades. Understanding these intricate networks may open avenues for incorporating immunotherapeutic agents alongside ALK inhibitors and VEGF-targeted treatments, crafting a multipronged assault against lung cancer.

The study’s methodology also leveraged cutting-edge imaging modalities and biomarker analyses to monitor tumor response dynamically. Advanced radiographic techniques allowed precise quantification of vascular changes and tumor burden, while circulating tumor DNA (ctDNA) assays provided real-time insights into molecular evolution, enabling personalized adjustments in therapeutic strategies. These sophisticated tools exemplify how translational research is tightly interwoven with clinical trials to accelerate discoveries from bench to bedside.

Beyond the immediate patient population, findings from ALEK-B may stimulate drug development aimed at novel combinations pairing tyrosine kinase inhibitors with anti-angiogenic drugs in other genetic contexts. Oncologists envision a future where such regimens become customizable based on comprehensive genomic and transcriptomic profiling, maximizing efficacy while minimizing toxicity.

In conclusion, the ALEK-B trial represents a bold step forward in the treatment of ALK-rearranged NSCLC. By strategically combining alectinib’s potent ALK inhibition with bevacizumab’s anti-angiogenic capabilities, researchers have laid the groundwork for a potentially transformative approach in managing this challenging disease. If validated in larger studies, this dual-targeted therapy could redefine first-line treatment paradigms, offering patients more durable responses and improved survival outcomes. The success of ALEK-B underscores the power of rational drug combinations designed not only to target oncogenic drivers but also to reshape the tumor microenvironment, heralding a new era of precision oncology.

—

Subject of Research: Combination therapy with alectinib and bevacizumab as a first-line treatment for ALK-rearranged non-small cell lung cancer

Article Title: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Article References:

Arrieta, O., Lara-Mejía, L., Rios-Garcia, E. et al. Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial. Nat Commun 16, 4553 (2025). https://doi.org/10.1038/s41467-025-59744-9

Image Credits: AI Generated

ENKTL is a rare subtype of non-Hodgkin lymphoma, often originating within the nasal cavity or other extranodal sites. This malignancy is distinctively associated with the Epstein–Barr virus (EBV), which is implicated in its pathogenesis. Notably, the disease shows a higher prevalence among East Asian populations compared to Western cohorts, spotlighting the importance of region-specific research and treatment paradigms. Patients with ENKTL who relapse or become refractory to standard chemotherapy face dismal prognoses, highlighting a critical unmet medical need that motivates ongoing scientific inquiry.

Building on years of molecular research at the National Cancer Centre Singapore (NCCS), investigators have leveraged genomic sequencing technologies to decode the genetic underpinnings of ENKTL. In a landmark discovery published in 2020, the NCCS Lymphoma Translational Research Laboratory identified mutations within the PD-L1 gene that disrupt its interaction with PD-1, a critical immune checkpoint pathway. This disruption contributes to immune evasion by tumor cells, suggesting that immune checkpoint inhibitors could restore immune surveillance in affected patients. This key insight provided the biological rationale for incorporating PD-1 blockade into therapeutic regimens.

Expanding on their genomic insights, NCCS researchers employed machine learning algorithms on a dataset of 260 ENKTL patient genomes sourced from Singapore, China, Belgium, and Taiwan. This analysis culminated in the development of a genomic prognostic model based on mutations in 13 genes, capable of predicting patient outcomes with high accuracy. Validated across international cohorts, this prognostic tool has the potential to revolutionize clinical decision-making, enabling more precise patient stratification and individualized therapy selection.

The collaborative synergy between NCCS and South Korea’s Consortium for Improving Survival of Lymphoma (CISL) propelled this translational research into a clinical trial setting. Commencing in 2021, the phase 2 trial enrolled 37 patients across six Korean centers, all diagnosed with relapsed or refractory ENKTL. The trial tested a combination of cemiplimab, a PD-1 immune checkpoint inhibitor, and isatuximab, a monoclonal antibody that targets CD38—a molecule implicated in immune resistance mechanisms. Through intravenous administration up to two years or until disease progression or toxicity occurred, this regimen aimed to tackle the tumor through complementary immunomodulatory mechanisms.

Results from the trial are striking. More than half of the patients, 51%, attained a complete response characterized by over an 80% reduction in tumor burden. An additional 14% achieved partial responses, culminating in an overall objective response rate (ORR) of 65%. The median duration of response was notable at 21 months, underscoring not only the efficacy but also the durability of the combined immunotherapy. These findings shine a beacon of hope for patients historically facing limited treatment options.

Genomic profiling conducted by NCCS validated earlier hypotheses regarding PD-L1 mutations as predictive biomarkers. Intriguingly, all three patients harboring the PD-L1 3’ UTR mutation achieved complete responses, confirming the translational relevance of this mutation for therapeutic responsiveness. Moreover, the prognostic model developed in 2022 was corroborated as a reliable predictor even as treatment landscapes evolve, reinforcing its utility for future clinical application.

Further immunophenotyping shed light on the tumor microenvironment, revealing that responders exhibited unusually elevated levels of regulatory T cells (Tregs). This observation opens a new avenue for biomarker discovery and possible therapeutic targeting. The role of Tregs in modulating anti-tumoral immunity is complex and may represent an additional layer through which ENKTL evades immune eradication.

Experts at NCCS emphasize that the integration of genomic biomarkers with immunotherapeutic strategies exemplifies the future of oncology—where molecular insights guide targeted, effective, and personalized treatment. Associate Professor Ong Choon Kiat, co-author of the study and head of NCCS’s lymphoma research division, noted that linking specific genetic abnormalities to therapeutic outcomes marks a pivotal advancement in understanding and combating ENKTL.

Co-first author Dr. Lim Jing Quan highlighted the critical role of international collaboration and technological innovation, emphasizing how next-generation sequencing and data analytics are crucial in deciphering tumor heterogeneity and resistance mechanisms. This multidisciplinary approach is vital for translating laboratory discoveries into tangible patient benefits.

Looking forward, NCCS researchers continue to probe the genomes of patients who did not respond to the combination therapy, aiming to unveil additional mutations and pathways that could serve as future drug targets. The atypical abundance of regulatory T cells hints at immune evasion mechanisms that may be amenable to novel interventions. Parallel retrospective analyses are underway to further validate the prognostic model and broaden its clinical impact, paving the way for precision oncology in ENKTL.

The successful deployment of cemiplimab and isatuximab combination therapy represents a landmark achievement in lymphoma treatment, potentially reshaping therapeutic standards for relapsed and refractory cases. Beyond its clinical significance, this study exemplifies the immense value of coupling deep molecular profiling with immunotherapy, offering a beacon of hope for patients afflicted by this challenging disease.

The National Cancer Centre Singapore continues to reinforce its position as a center of excellence in cancer research and care. Equipped with state-of-the-art facilities including the Goh Cheng Liang Proton Therapy Centre, NCCS is at the forefront of blending innovative treatment modalities with precision medicine, expanding the horizons of cancer therapeutics regionally and globally.

Subject of Research: People

Article Title: Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma

News Publication Date: 16 April 2025

Web References:
http://dx.doi.org/10.1182/blood.2024027109

References:
Lim, J. Q., Huang, D., Tang, T., et al. (2020). Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia, 34(12), 3413–3419.
Lim, J. Q., Huang, D., Chan, J. Y., et al. (2022). A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort. American Journal of Hematology, 97(9), 1159–1169.

Image Credits: National Cancer Centre Singapore

Keywords: Extranodal NK/T-cell lymphoma, ENKTL, immunotherapy, cemiplimab, isatuximab, PD-1, CD38, genomic biomarkers, personalized medicine, lymphoma, phase 2 clinical trial, regulatory T cells, NCCS